A Phase Ib/II, open-label, multicenter study of INC280 in combination with buparlisib in adult patients with recurrent glioblastoma

A phase II, multicenter, three-cohort study of oral cMET inhibitor INC280 in adult patients with EGFR wild-type (wt), advanced non-small cell lung cancer (NSCLC) who have received one or two prior lines of systemic therapy for advanced/metastatic disease

arcT – Autoinflammation Reference Center

Damage Score ARDIS – Damage Score: Organschäden bei autoinflammatorischen Erkrankungen

INDIX – Patient derived xenografts

MARCAR – bioMARkers and molecular tumour classification for non-genotoxic CARcinogenesis

PACIFIC – Nichtinterventionelle Studie: Beobachtung im Behandlungsalltag

Visiten Pulmologie